AVBP — ArriVent Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $854.11m
- $553.85m
- 26
- 22
- 36
- 16
Annual cashflow statement for ArriVent Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -51.6 | -36.9 | -69.3 | -80.5 |
| Non-Cash Items | 43 | 0.424 | 0.895 | 3.21 |
| Purchased R&D | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -3.94 | -7.15 | 12.6 | 7.07 |
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Cash from Operating Activities | -12.6 | -43.6 | -55.8 | -70.2 |
| Other Investing Cash Flow Items | -40 | 0 | 0 | -192 |
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | -40 | 0 | 0 | -192 |
| Financing Cash Flow Items | — | — | -2.41 | — |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 89.9 | 170 | 42.9 | 187 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 37.3 | 126 | -13 | -76.1 |